Acute Pain, Chronic Pain
Conditions
Keywords
Knee arthroplasty, Dexamethasone, Acute pain, Chronic pain
Brief summary
The purpose of the study is three fold. First to determine the ideal dose of dexamethasone intraoperatively that will reduce acute pain and opioid consumption. Second determine if dexamethasone at the time of surgery reduces chronic pain following total knee arthroplasty and finally determine if a pro-inflammatory environment makes patients susceptible to chronic pain after surgery and can dexamethasone alter this environment. Patients undergoing total knee arthroplasty will be randomized to four groups ( 0mg, 6mg, 12mg and 24mg dexamethasone) and assessments will be made of acute and chronic pain and quality of life measures. Blood samples will be drawn to assess Interleukin levels and for Macrophage sorting. For the primary efficacy endpoint of reduction of opioid consumption over 24 hours after surgery the dexamethasone regimen group will be compared to standard of care group using t-test. For comparisons of the secondary efficacy endpoints, t-test, Chi-square test and Fisher's Exact test will be used. Risks of this study include the risks of venipuncture and intravenous dexamethasone administration.
Detailed description
This is a Phase IV single center, prospective, randomized, double-blind, dose response study designed to evaluate the optimum dose of dexamethasone to administer as an analgesic in total knee arthroplasty surgery. Randomization will be performed using computer software and the randomization order will be written and enclosed in envelopes in the study office. A total of 40 patients will be randomized to receive different doses of dexamethasone intravenously at induction of anesthesia with the same dose repeated 24 hours later. The dose groups are: 0mg, 6mg, 12mg, 24mg. The groups will be evenly divided into 10 subjects in each group. Patients will be cared for using established standard of care anesthetic and multi modal analgesia pathway used clinically at Duke University Medical Center. Knee arthroplasty generally occurs in patients over 65 years of age and an inclusion criteria is age 55 years or older is included in the study. Regional anesthesia is more technically challenging in morbidly obese patients. Because of an increased failure rate of regional anesthesia in morbidly obese patients an upper limit BMI of 40 is included in the study design. Anesthetic regime. The anesthesia will be standard of care apart from the administration of the study drug. Study Drug. After randomization the first dose of intravenous dexamethasone will be administered by the anesthesia care team immediately before surgery. The subject and study personnel will be blinded to the dose. The patient will be sedated and the study personnel will not be in the operating room. The dose will be recorded on the anesthesia record. The second dose of dexamethasone will be prescribed by the PI. This will be prescribed electronically to be administered to the subject on the floor 24 hours after the first dose. Surgery The surgery will proceed normally with no difference for the study. Postoperative Pain Management Patients in all groups will receive standard of care postoperative analgesic regimen. Blood Samples Blood will be drawn in preop holding (Time 0) for Interleukin 6, Interleukin10 and for macrophage sorting. Blood samples will be repeated for Interleukin 6 and Interleukin10 at 10-14, 22-26 and 33-39hours after surgery. Blood samples for macrophage sorting will be repeated at 33-39hours. The total blood collected will be 30ml on the day of surgery and 10 ml post operative day 1 for an overall total of 40cc.
Interventions
DRUGDexamethasone
Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
OTHERPlacebo
Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
Sponsors
Duke University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients scheduled to undergo unilateral total knee arthroplasty. * American Society of Anesthesiology (ASA) Physical Class 1-3. * BMI \<40 kg/m2
Exclusion criteria
* Revision surgery. * Bilateral total knee arthroplasty. * Unicompartmental knee arthroplasty. * Patients with a contraindication to regional anesthesia. This includes abnormal clotting, skin infection in groin or near the back, the presence of neurological disorders or anatomical abnormalities of the vertebral column. * Contraindications or known drug interactions with dexamethasone. * Use of any of the following medications within the times specified before surgery: * Long-acting opioid medication within 3 days. * Any opioid medication within 24 hours. * Body weight less than 50 kilograms (\ 110 pounds). * Planned administration of another investigational product or procedure during the subject's participation in this study. * Suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years. * Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance. * Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject's postoperative course. * Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function (Ejection fraction under 35%), epilepsy, myasthenia gravis), severe renal impairment (creatinine \> 1.8), comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Visual Analogue Pain Score | 6, 12, 18, 24, 36 hours after surgery | Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where 0 represents no pain and 10 represents worst pain ever. |
| Change in Opioid Consumption | 6, 12, 18, 24, 36 hours after surgery | mg of morphine equivalents |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 30 days, 3 and 6 months following surgery | The Western Ontario and McMaster Universities Osteoarthritis Index measures 17 items for functional limitation (score range 0-68). Higher score = higher difficulty with the task. |
| Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | Baseline at enrollment, 3 months and 6 months after surgery | Brief pain inventory questionnaire will be administered generating a score (0-40). Higher scores reflect higher perceived pain. |
| Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | Baseline at Enrollment, 3 and 6 months after surgery | Brief pain inventory questionnaire will be administered generating a score (0-70). Higher scores reflect higher perceived pain interference. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Change in Macrophage Proliferation | Samples will be taken immediately pre incision and will be repeated at 33-39hours | Macrophage totals and differentiation will be assessed within patients and between groups. |
| Change in Interleukin 6 and 10 Levels | Sample immediately prior to incision and at 10-14, 22-26 and 33-39hours after surgery. | Interleukin levels and the ratio will assess pro and anti inflammatory processes in the patients |
Countries
United States
Participant flow
Recruitment details
45 participants signed consent. 3 participants withdrew prior to randomization
Participants by arm
| Arm | Count |
|---|---|
| Dexamethasone 6mg Patients receive 6mg iv dexamethasone at surgical incision and a repeat dose of 6mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group | 11 |
| Dexamethasone 12mg Patients receive 12mg iv dexamethasone at surgical incision and a repeat dose of 12mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group | 10 |
| Dexamethasone 24mg Patients receive 24mg iv dexamethasone at surgical incision and a repeat dose of 24mg of dexamethasone 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Dexamethasone: Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group | 10 |
| Placebo Patients receive a placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. Pain scores and opioid consumption will be assessed using iv opioid patient controlled analgesia totals.
Placebo: Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision. | 11 |
| Total | 42 |
Baseline characteristics
| Characteristic | Dexamethasone 6mg | Dexamethasone 12mg | Dexamethasone 24mg | Placebo | Total |
|---|---|---|---|---|---|
| Age, Continuous | 68.06 years STANDARD_DEVIATION 8.74 | 66.56 years STANDARD_DEVIATION 8.32 | 64.14 years STANDARD_DEVIATION 6.43 | 69.45 years STANDARD_DEVIATION 5.45 | 67.13 years STANDARD_DEVIATION 7.35 |
| Sex: Female, Male Female | 7 Participants | 4 Participants | 4 Participants | 8 Participants | 23 Participants |
| Sex: Female, Male Male | 4 Participants | 6 Participants | 6 Participants | 3 Participants | 19 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 1 / 11 | 2 / 10 | 5 / 10 | 6 / 11 |
| serious Total, serious adverse events | 0 / 11 | 0 / 10 | 0 / 10 | 0 / 11 |
Outcome results
Primary
Change in Opioid Consumption
mg of morphine equivalents
Time frame: 6, 12, 18, 24, 36 hours after surgery
Population: Participants who completed pain score at specified time-points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexamethasone 6mg | Change in Opioid Consumption | 6 hours | 21.10 mg of morphine equivalents | Standard Deviation 15.94 |
| Dexamethasone 6mg | Change in Opioid Consumption | 12 hours | 42.24 mg of morphine equivalents | Standard Deviation 50.16 |
| Dexamethasone 6mg | Change in Opioid Consumption | 18 hours | 20.30 mg of morphine equivalents | Standard Deviation 16.77 |
| Dexamethasone 6mg | Change in Opioid Consumption | 36 hours | 27.00 mg of morphine equivalents | Standard Deviation 25.22 |
| Dexamethasone 6mg | Change in Opioid Consumption | 24 hours | 25.50 mg of morphine equivalents | Standard Deviation 15.69 |
| Dexamethasone 12mg | Change in Opioid Consumption | 24 hours | 20.91 mg of morphine equivalents | Standard Deviation 17.93 |
| Dexamethasone 12mg | Change in Opioid Consumption | 36 hours | 24.61 mg of morphine equivalents | Standard Deviation 17.13 |
| Dexamethasone 12mg | Change in Opioid Consumption | 12 hours | 27.24 mg of morphine equivalents | Standard Deviation 30.03 |
| Dexamethasone 12mg | Change in Opioid Consumption | 6 hours | 22.20 mg of morphine equivalents | Standard Deviation 23.54 |
| Dexamethasone 12mg | Change in Opioid Consumption | 18 hours | 16.86 mg of morphine equivalents | Standard Deviation 16.93 |
| Dexamethasone 24mg | Change in Opioid Consumption | 36 hours | 36.43 mg of morphine equivalents | Standard Deviation 26.25 |
| Dexamethasone 24mg | Change in Opioid Consumption | 12 hours | 54.23 mg of morphine equivalents | Standard Deviation 35.8 |
| Dexamethasone 24mg | Change in Opioid Consumption | 24 hours | 25.86 mg of morphine equivalents | Standard Deviation 14.8 |
| Dexamethasone 24mg | Change in Opioid Consumption | 18 hours | 43.16 mg of morphine equivalents | Standard Deviation 55.34 |
| Dexamethasone 24mg | Change in Opioid Consumption | 6 hours | 11.77 mg of morphine equivalents | Standard Deviation 11.75 |
| Placebo | Change in Opioid Consumption | 6 hours | 33.50 mg of morphine equivalents | Standard Deviation 21.84 |
| Placebo | Change in Opioid Consumption | 12 hours | 32.25 mg of morphine equivalents | Standard Deviation 30.74 |
| Placebo | Change in Opioid Consumption | 18 hours | 29.75 mg of morphine equivalents | Standard Deviation 37.12 |
| Placebo | Change in Opioid Consumption | 36 hours | 21.29 mg of morphine equivalents | Standard Deviation 13.59 |
| Placebo | Change in Opioid Consumption | 24 hours | 23.79 mg of morphine equivalents | Standard Deviation 21.79 |
p-value: 0.733t-test, 2 sided
p-value: 0.181t-test, 2 sided
p-value: 0.364t-test, 2 sided
p-value: 0.605t-test, 2 sided
p-value: 0.6t-test, 2 sided
Primary
Change in Visual Analogue Pain Score
Pain scores at rest and with activity using a verbal rating scales (VRS) of 0-10, where 0 represents no pain and 10 represents worst pain ever.
Time frame: 6, 12, 18, 24, 36 hours after surgery
Population: Participants who completed pain score at specified time-points.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 12 hour at rest | 2.82 units on a scale | Standard Deviation 1.99 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 6 hour with movement | 4.36 units on a scale | Standard Deviation 2.42 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 12 hour with movement | 5.75 units on a scale | Standard Deviation 2.25 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 18 hour at rest | 1.55 units on a scale | Standard Deviation 1.86 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 24 hour at rest | 2.91 units on a scale | Standard Deviation 2.34 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 24 hour with movement | 4.82 units on a scale | Standard Deviation 2.68 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 36 hour at rest | 3.00 units on a scale | Standard Deviation 2.24 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 36 hour with movement | 5.29 units on a scale | Standard Deviation 1.6 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 6 hour at rest | 3.09 units on a scale | Standard Deviation 1.45 |
| Dexamethasone 6mg | Change in Visual Analogue Pain Score | 18 hour with movement | 4.00 units on a scale | Standard Deviation 3.16 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 12 hour with movement | 6.11 units on a scale | Standard Deviation 1.76 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 18 hour at rest | 2.70 units on a scale | Standard Deviation 2.45 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 18 hour with movement | 5.43 units on a scale | Standard Deviation 2.99 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 24 hour at rest | 3.50 units on a scale | Standard Deviation 2.27 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 6 hour at rest | 4.80 units on a scale | Standard Deviation 2.2 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 24 hour with movement | 6.50 units on a scale | Standard Deviation 2.07 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 36 hour at rest | 3.86 units on a scale | Standard Deviation 2.54 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 6 hour with movement | 6.50 units on a scale | Standard Deviation 3.1 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 12 hour at rest | 3.50 units on a scale | Standard Deviation 1.96 |
| Dexamethasone 12mg | Change in Visual Analogue Pain Score | 36 hour with movement | 7.00 units on a scale | Standard Deviation 1.79 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 24 hour with movement | 6.38 units on a scale | Standard Deviation 2.33 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 12 hour with movement | 6.00 units on a scale | Standard Deviation 2.77 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 6 hour with movement | 5.88 units on a scale | Standard Deviation 2.47 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 36 hour with movement | 6.83 units on a scale | Standard Deviation 2.23 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 6 hour at rest | 3.56 units on a scale | Standard Deviation 2.74 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 18 hour at rest | 2.56 units on a scale | Standard Deviation 2.4 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 18 hour with movement | 4.63 units on a scale | Standard Deviation 2.88 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 24 hour at rest | 3.67 units on a scale | Standard Deviation 2.65 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 36 hour at rest | 4.43 units on a scale | Standard Deviation 2.3 |
| Dexamethasone 24mg | Change in Visual Analogue Pain Score | 12 hour at rest | 2.78 units on a scale | Standard Deviation 1.86 |
| Placebo | Change in Visual Analogue Pain Score | 18 hour at rest | 5.09 units on a scale | Standard Deviation 2.39 |
| Placebo | Change in Visual Analogue Pain Score | 24 hour at rest | 4.09 units on a scale | Standard Deviation 2.84 |
| Placebo | Change in Visual Analogue Pain Score | 6 hour with movement | 7.33 units on a scale | Standard Deviation 1.8 |
| Placebo | Change in Visual Analogue Pain Score | 24 hour with movement | 7.20 units on a scale | Standard Deviation 2.15 |
| Placebo | Change in Visual Analogue Pain Score | 12 hour at rest | 5.18 units on a scale | Standard Deviation 2.99 |
| Placebo | Change in Visual Analogue Pain Score | 36 hour at rest | 2.89 units on a scale | Standard Deviation 1.69 |
| Placebo | Change in Visual Analogue Pain Score | 12 hour with movement | 7.30 units on a scale | Standard Deviation 3.23 |
| Placebo | Change in Visual Analogue Pain Score | 6 hour at rest | 5.5 units on a scale | Standard Deviation 2.54 |
| Placebo | Change in Visual Analogue Pain Score | 18 hour with movement | 6.90 units on a scale | Standard Deviation 3 |
| Placebo | Change in Visual Analogue Pain Score | 36 hour with movement | 6.33 units on a scale | Standard Deviation 1.94 |
p-value: 0.052t-test, 2 sided
p-value: 0.064t-test, 2 sided
p-value: 0.139t-test, 2 sided
p-value: 0.35t-test, 2 sided
p-value: 0.021t-test, 2 sided
p-value: 0.198t-test, 2 sided
p-value: 0.806t-test, 2 sided
p-value: 0.228t-test, 2 sided
p-value: 0.457t-test, 2 sided
p-value: 0.394t-test, 2 sided
Secondary
Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire
Brief pain inventory questionnaire will be administered generating a score (0-40). Higher scores reflect higher perceived pain.
Time frame: Baseline at enrollment, 3 months and 6 months after surgery
Population: Participants who completed questionnaire
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexamethasone 6mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Dexamethasone 6mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 6 months | 0 units on a scale |
| Dexamethasone 6mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 3 months | 1 units on a scale |
| Dexamethasone 12mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 6 months | 2.5 units on a scale |
| Dexamethasone 12mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 3 months | 0.5 units on a scale |
| Dexamethasone 12mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Dexamethasone 24mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 6 months | 1 units on a scale |
| Dexamethasone 24mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 3 months | 2 units on a scale |
| Dexamethasone 24mg | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Placebo | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 3 months | 2 units on a scale |
| Placebo | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | Baseline | 4 units on a scale |
| Placebo | Change in Chronic Pain as Measured by Brief Pain Inventory Questionnaire | 6 months | 0 units on a scale |
Secondary
Change in Functional Status as Measured by Brief Pain Inventory Questionnaire
Brief pain inventory questionnaire will be administered generating a score (0-70). Higher scores reflect higher perceived pain interference.
Time frame: Baseline at Enrollment, 3 and 6 months after surgery
Population: Participants who completed questionnaire
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexamethasone 6mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Dexamethasone 6mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 3 Months | 0 units on a scale |
| Dexamethasone 6mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 6 Months | 0 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 3 Months | 5 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 6 Months | 1 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 6 Months | 0 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | Baseline | 5 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 3 Months | 0 units on a scale |
| Placebo | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 3 Months | 1.5 units on a scale |
| Placebo | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | 6 Months | 0 units on a scale |
| Placebo | Change in Functional Status as Measured by Brief Pain Inventory Questionnaire | Baseline | 4 units on a scale |
Secondary
Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index
The Western Ontario and McMaster Universities Osteoarthritis Index measures 17 items for functional limitation (score range 0-68). Higher score = higher difficulty with the task.
Time frame: 30 days, 3 and 6 months following surgery
Population: Participants who completed questionnaire
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Dexamethasone 6mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 30 Days | 25 units on a scale |
| Dexamethasone 6mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 3 months | 17 units on a scale |
| Dexamethasone 6mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 6 months | 14 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 3 months | 32 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 6 months | 24.5 units on a scale |
| Dexamethasone 12mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 30 Days | 29.5 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 30 Days | 42 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 3 months | 19 units on a scale |
| Dexamethasone 24mg | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 6 months | 17 units on a scale |
| Placebo | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 6 months | 16 units on a scale |
| Placebo | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 3 months | 24 units on a scale |
| Placebo | Change in Functional Status as Measured by Western Ontario and McMaster Universities Osteoarthritis Index | 30 Days | 30 units on a scale |
Other Pre-specified
Change in Interleukin 6 and 10 Levels
Interleukin levels and the ratio will assess pro and anti inflammatory processes in the patients
Time frame: Sample immediately prior to incision and at 10-14, 22-26 and 33-39hours after surgery.
Other Pre-specified
Change in Macrophage Proliferation
Macrophage totals and differentiation will be assessed within patients and between groups.
Time frame: Samples will be taken immediately pre incision and will be repeated at 33-39hours